Lantern Pharma Inc

Market Cap

$48M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.59+$0.48 (+15.43%)

Jun 5, 2026

52W High $5.3252W Low $1.12

Company Details

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adeno...

CEO

—

IPO Date

Jun 11, 2020

Website

www.lanternpharma.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$16M

EPS (Diluted)

Free Cash Flow

-$15M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 15, 2026

$0-100.0%

FY 2025

Mar 30, 2026

Q4 2025

Mar 30, 2026

$0-100.0%

Q3 2025

Nov 12, 2025

Q2 2025

Aug 13, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee